Skip to content
value.today
Ovid Therapeutics Inc. logo

Ovid Therapeutics Inc.

OVID
$427 Mmarket cap on Oct 16, 2026+89.6% since Jan 2024
1D
+3.2%
Compare
World rank
#13,275
Revenue
$7 M
For year ending December-2025
Net income
$-17 M
-240.1% margin
SEC filing
Employees
23
As of December 31, 2025
SEC filing

Ovid Therapeutics Inc. in brief

Ovid Therapeutics Inc. is a listed company in the Biotechnology industry, based in New York, New York, USA. It was founded in 2014. Its market value was $427 M on 16 October 2026, which makes it the 13,275th largest listed company in the world and the 2,634th largest in the USA on this site. In the year to December 2025 it had sales of $7 M and a net loss of $17 M. It employs about 23 people and Margaret A. Alexander is its chief executive. Its largest business segments by sales in 2025 were Reportable (100%). Its shares trade under the symbol OVID (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Ovid Therapeutics Inc.

Ovid is a biopharmaceutical company that is dedicated to developing small molecule medicines for brain disorders with significant unmet need. These potential medicines targeting the central nervous system are designed to potentially halt the course of brain disease by quelling neuronal hyperexcitation and alleviating the most impactful patient symptoms. We seek to address fundamental biological targets in the brain that are implicated in neuronal hyperexcitability, such as neurotransmitters and dysregulated ion channels. By mitigating excessive neuronal hyperexcitation with differentiated medicines, we believe we can unlock substantial scientific, therapeutic and commercial opportunities across a range of neurological and psychiatric conditions that have few therapeutic options today, both impacting patients’ lives and creating long-term stockholder value.

From the company's annual report filed with the US SEC: read the report

Ovid Therapeutics Inc. timeline

4 events, 2014–2021
  1. 2014
  2. 🏁
    · approximate
    Founded
  3. 2015
  4. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  5. 2017
  6. 🔔
    Initial public offering on Nasdaq
    Final prospectus filed with the SEC on 5 May 2017; shares registered for exchange trading on 4 May 2017.
  7. 2021
  8. 💰
    Record revenue of $208 million
    FY2021, the highest of the 6 years on record.

Events of Ovid Therapeutics Inc. from the company record, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$143 M$285 M$428 M$570 M2020202120222023202420252026

World rank over time

▲ up 2,623 places since 2020
2020-01-01: #15928#15,92820202021-01-01: #16698#16,69820212022-01-07: #18264#18,26420222022-12-25: #20673#20,67320222023-07-30: #16912#16,91220232024-01-05: #17261#17,26120242026-03-08: #8635#8,63520262026-08-01: #12044#12,04420262026-10-14: #13497#13,49720262026-10-16: #13305#13,3052026

Rank in USA: #3,239 (Jan 2020) · #3,451 (Jan 2021) · #3,736 (Jan 2022) · #4,126 (Dec 2022) · #3,420 (Jul 2023) · #3,158 (Jan 2024) · #1,605 (Mar 2026) · #2,504 (Aug 2026) · #2,643 (Oct 2026) · #2,637 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
58.8×
Price / book
3.3×
Free cash flow yield
-9.0%
Net margin
-240.1%
Operating margin
-585.4%
Return on equity
-13.3%
Liabilities / assets
13.4%
Revenue growth
+1171.9%
R&D / revenue
352.8%
Revenue per employee
$315 K
Profit per employee
$-757 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue —, net income $-52M—FY18Fiscal year ending Dec 2019: revenue —, net income $-60M—FY19Fiscal year ending Dec 2020: revenue $13M, net income $-81M$13MFY20Fiscal year ending Dec 2021: revenue $208M, net income $123M$208MFY21Fiscal year ending Dec 2022: revenue $2M, net income $-54M$2MFY22Fiscal year ending Dec 2023: revenue $0M, net income $-52M$0MFY23Fiscal year ending Dec 2024: revenue $1M, net income $-26M$1MFY24Fiscal year ending Dec 2025: revenue $7M, net income $-17M$7MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$7M+1171.9%$-42M$-17M-240.1%
Dec 2024$1M+46.2%$-62M$-26M-4636.8%
Dec 2023$0M-74.0%$-59M$-52M-13420.5%
Dec 2022$2M-99.3%$-56M$-54M-3611.3%
Dec 2021$208M+1551.2%$124M$123M58.9%
Dec 2020$13M—$-81M$-81M-642.2%
Dec 2019——$-61M$-60M—
Dec 2018——$-53M$-52M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-38M$0M$-38M——
Dec 2024$-56M$0M$-56M——
Dec 2023$-46M$0M$-46M$-0.74—
Dec 2022$-55M$1M$-56M$-0.77—
Dec 2021$119M$0M$118M$1.76—
Dec 2020$-52M$0M$-52M$-1.39—
Dec 2019$-51M$0M$-51M——
Dec 2018$-46M$0M$-46M$-2.11—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue $0M, net income $-9M$0MDec ’24Three months to Mar 2025: revenue $0M, net income $-10M$0MMar ’25Three months to Jun 2025: revenue $6M, net income $-5M$6MJun ’25Three months to Sep 2025: revenue $0M, net income $-12M$0MSep ’25Three months to Dec 2025 (from the annual report): revenue $1M, net income $10M$1MDec ’25Three months to Mar 2026: revenue —, net income $-17M—Mar ’26Three months to Jun 2026: revenue $1M, net income $-15M$1MJun ’26Three months to Sep 2026: revenue —, net income $-21M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-21M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Ovid Therapeutics Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$7 M
Operating income
$-42 M
Net income
$-17 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$151 M
Total liabilities
$20 M
Total equity
$131 M

As of December-2025

Top 100 institutional investors in Ovid Therapeutics Inc.#

As of Sep 30, 2026
129 institutions held 148.4 M shares (about 78.6% of the shares outstanding) on Sep 30, 2026. The ten largest hold 50.1%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Ovid Therapeutics Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Janus Henderson Group Ltd.20,741,234—10.99%$52 MNov 16, 2026
2BlackRock, Inc.12,050,453+1,226,973 (+11.34%)6.38%$30 MNov 13, 2026
3Eventide Asset Management, LLC11,812,2410 (0.00%)6.26%$29 MNov 13, 2026
4Affinity Asset Advisors, LLC10,144,5620 (0.00%)5.38%$25 MNov 13, 2026
5Vanguard Capital Management LLC7,828,361+68,247 (+0.88%)4.15%$19 MNov 13, 2026
6Balyasny Asset Management L.P.7,118,278+399,202 (+5.94%)3.77%$18 MNov 16, 2026
7Braidwell LP6,582,421+662,957 (+11.20%)3.49%$16 MNov 16, 2026
8State Street Corp6,203,161-1,697,604 (-21.49%)3.29%$15 MNov 12, 2026
9Adage Capital Partners GP, L.L.C.6,163,7810 (0.00%)3.27%$15 MNov 16, 2026
10Federated Hermes, Inc.5,951,6660 (0.00%)3.15%$15 MNov 12, 2026
11Silverarc Capital Management, LLC5,950,000+2,848,871 (+91.87%)3.15%$15 MNov 12, 2026
12Ra Capital Management, L.P.5,598,200-4,902,768 (-46.69%)2.97%$14 MNov 16, 2026
13ADAR1 Capital Management, LLC4,560,813-2,856,666 (-38.51%)2.42%$11 MNov 16, 2026
14Geode Capital Management, LLC4,300,950+228,297 (+5.61%)2.28%$11 MNov 6, 2026
15Integral Health Asset Management, LLC3,500,000New1.85%$9 MNov 16, 2026
16Point72 Asset Management, L.P.2,549,273+603,546 (+31.02%)1.35%$6 MNov 16, 2026
17Ikarian Capital, LLC2,119,704-150,000 (-6.61%)1.12%$5 MNov 16, 2026
18Vanguard Portfolio Management LLC1,666,985+636,042 (+61.70%)0.88%$4 MNov 13, 2026
19Sphera Funds Management LTD.1,600,000+247,000 (+18.26%)0.85%$4 MNov 16, 2026
20Northern Trust Corp1,302,864+56,725 (+4.55%)0.69%$3 MNov 16, 2026
21Stempoint Capital LP1,287,804-1,129,479 (-46.73%)0.68%$3 MNov 16, 2026
22Vanguard Fiduciary Trust Co1,195,586+54,833 (+4.81%)0.63%$3 MNov 13, 2026
23Rosalind Advisors, Inc.1,107,9940 (0.00%)0.59%$3 MNov 16, 2026
24Propel Bio Management, LLC1,018,721-96,817 (-8.68%)0.54%$3 MNov 13, 2026
25Atom Investors LP1,016,854+765,018 (+303.78%)0.54%$3 MNov 16, 2026
Show all 100: investors 26 to 100
Institutional investors 26 to 100 in Ovid Therapeutics Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Sio Capital Management, LLC1,005,3340 (0.00%)0.53%$3 MNov 16, 2026
27Nuveen, LLC893,2540 (0.00%)0.47%$2 MNov 10, 2026
28Ensign Peak Advisors, Inc825,852-162,232 (-16.42%)0.44%$2 MNov 12, 2026
29Wells Fargo & Company/mn732,590-93,616 (-11.33%)0.39%$2 MNov 16, 2026
30UBS Group AG711,575+252,658 (+55.06%)0.38%$2 MNov 10, 2026
31Boothbay Fund Management, LLC689,001-48,757 (-6.61%)0.37%$2 MNov 16, 2026
32Goldman Sachs Group Inc614,348+281,656 (+84.66%)0.33%$2 MNov 16, 2026
33FMR LLC575,488+536,478 (+1375.23%)0.30%$1 MNov 10, 2026
34Charles Schwab Investment Management Inc558,341+114,299 (+25.74%)0.30%$1 MNov 16, 2026
35Wellington Management Group LLP550,556+447,156 (+432.45%)0.29%$1 MNov 16, 2026
36Barclays PLC510,623+476,503 (+1396.55%)0.27%$1 MNov 6, 2026
37Bank Of America Corp /de/482,268+72,778 (+17.77%)0.26%$1 MNov 16, 2026
38Walleye Capital LLC479,083New0.25%$1 MNov 13, 2026
39Bank of New York Mellon Corp451,863+35,545 (+8.54%)0.24%$1 MNov 5, 2026
40Morgan Stanley421,089+364,170 (+639.80%)0.22%$1 MNov 13, 2026
41Dimensional Fund Advisors LP378,968-8,799 (-2.27%)0.20%$1 MNov 4, 2026
42Two Sigma Investments, LP331,445-500,933 (-60.18%)0.18%$1 MNov 16, 2026
43American Century Companies Inc315,023+145,641 (+85.98%)0.17%$1 MNov 12, 2026
44Informed Momentum Co LLC266,204+6,573 (+2.53%)0.14%$1 MNov 16, 2026
45Panagora Asset Management Inc248,628New0.13%$1 MNov 12, 2026
46Squarepoint Ops LLC247,799+228,862 (+1208.54%)0.13%$1 MNov 9, 2026
47Schonfeld Strategic Advisors LLC222,127+187,078 (+533.76%)0.12%$1 MNov 16, 2026
48Parkman Healthcare Partners LLC215,462+17,515 (+8.85%)0.11%$1 MNov 16, 2026
49Invesco Ltd.212,315+37,415 (+21.39%)0.11%$1 MNov 12, 2026
50SEI Investments Co210,671+13,986 (+7.11%)0.11%$1 MNov 10, 2026
51Rhumbline Advisers182,215+12,076 (+7.10%)0.10%$0 MNov 10, 2026
52CIBC World Market Inc.172,820-46,031 (-21.03%)0.09%$0 MNov 10, 2026
53Stifel Financial Corp164,713New0.09%$0 MNov 12, 2026
54Vanguard Global Advisers, LLC142,707+72,180 (+102.34%)0.08%$0 MNov 13, 2026
55Deutsche Bank AG\130,660-18,731 (-12.54%)0.07%$0 MNov 6, 2026
56Velan Capital Investment Management LP130,0000 (0.00%)0.07%$0 MNov 16, 2026
57Price T Rowe Associates Inc /MD/125,7250 (0.00%)0.07%$0 MNov 16, 2026
58Rafferty Asset Management, LLC120,483-16,291 (-11.91%)0.06%$0 MNov 13, 2026
59D. E. Shaw & Co., Inc.101,940+65,063 (+176.43%)0.05%$0 MNov 16, 2026
60MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.88,389+2,291 (+2.66%)0.05%$0 MNov 16, 2026
61Jpmorgan Chase & Co82,988+19,506 (+30.73%)0.04%$0 MNov 12, 2026
62Sovereign Financial Group, Inc.80,000+50,000 (+166.67%)0.04%$0 MNov 12, 2026
63MetLife Investment Management, LLC78,564-12,023 (-13.27%)0.04%$0 MNov 16, 2026
64LPL Financial LLC65,131+15,031 (+30.00%)0.03%$0 MNov 6, 2026
65Alliancebernstein L.P.63,130-15,130 (-19.33%)0.03%$0 MNov 16, 2026
66Citigroup Inc59,686-131,372 (-68.76%)0.03%$0 MNov 4, 2026
67Bridgeway Capital Management, LLC55,434-40,000 (-41.91%)0.03%$0 MNov 16, 2026
68Spark Investment Management LLC55,200+23,400 (+73.58%)0.03%$0 MNov 13, 2026
69Millennium Management LLC55,134+22,839 (+70.72%)0.03%$0 MNov 16, 2026
70Empowered Funds, LLC51,234-40,000 (-43.84%)0.03%$0 MNov 13, 2026
71Police & Firemen's Retirement System of New Jersey45,1610 (0.00%)0.02%$0 MNov 9, 2026
72Manufacturers Life Insurance Company, The44,424+3,514 (+8.59%)0.02%$0 MNov 13, 2026
73Profund Advisors LLC44,074-25,625 (-36.77%)0.02%$0 MOct 29, 2026
74BNP Paribas Financial Markets43,814+19,938 (+83.51%)0.02%$0 MNov 12, 2026
75New York State Common Retirement Fund35,4000 (0.00%)0.02%$0 MNov 17, 2026
76Voya Investment Management LLC32,419+3,141 (+10.73%)0.02%$0 MNov 10, 2026
77Susquehanna International Group, LLP28,913-41,687 (-59.05%)0.02%$0 MNov 16, 2026
78Blair William & Co/il28,8390 (0.00%)0.02%$0 MNov 10, 2026
79Abel Hall, LLC28,499+175 (+0.62%)0.02%$0 MOct 19, 2026
80First Manhattan Co. LLC.26,0000 (0.00%)0.01%$0 MNov 16, 2026
81Prudential Financial Inc25,945+2,850 (+12.34%)0.01%$0 MNov 16, 2026
82Fred Alger Management, LLC23,721New0.01%$0 MNov 16, 2026
83Group One Trading LLC22,580+3,917 (+20.99%)0.01%$0 MNov 10, 2026
84Creative Planning21,110+112 (+0.53%)0.01%$0 MNov 2, 2026
85Total Clarity Wealth Management, Inc.20,961-6,450 (-23.53%)0.01%$0 MOct 26, 2026
86StoneX Group Inc.20,782New0.01%$0 MNov 3, 2026
87ProShare Advisors LLC20,737+688 (+3.43%)0.01%$0 MOct 29, 2026
88Victory Capital Management Inc20,596+1,248 (+6.45%)0.01%$0 MNov 10, 2026
89Caitong International Asset Management Co., Ltd20,203+6,815 (+50.90%)0.01%$0 MOct 29, 2026
90Benin Management CORP19,0000 (0.00%)0.01%$0 MOct 22, 2026
91TLS Advisors LLC18,8580 (0.00%)0.01%$0 MNov 16, 2026
92Focus Advisor Solutions, LLC17,875-2,125 (-10.62%)0.01%$0 MNov 10, 2026
93Assenagon Asset Management S.A.17,544-17,544 (-50.00%)0.01%$0 MOct 15, 2026
94Cetera Investment Advisers17,0000 (0.00%)0.01%$0 MNov 13, 2026
95Legal & General Group Plc16,351+1,493 (+10.05%)0.01%$0 MNov 16, 2026
96CIBC Bancorp USA Inc.16,328New0.01%$0 MNov 13, 2026
97XTX Topco Ltd16,265-18,075 (-52.64%)0.01%$0 MNov 16, 2026
98Royal Bank Of Canada15,460+10,668 (+222.62%)0.01%$0 MNov 16, 2026
99Xponance LLC15,089+529 (+3.63%)0.01%$0 MNov 3, 2026
100Ameritas Investment Partners, Inc.13,8960 (0.00%)0.01%$0 MNov 13, 2026

All 129 institutional investors, with who bought and sold →

Mutual funds holding Ovid Therapeutics Inc.#

70 funds hold shares worth $84 M (about 17.3% of the company). Since their previous reports 66 added shares and 2 sold, buying $46 M net.
Mutual funds holding Ovid Therapeutics Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.5.65 M$15 M3.0%<0.01%+48%Jun 30, 2026
🇺🇸 State Street SPDR S&P Biotech ETFSSGA Funds Management, Inc.4.92 M$13 M2.6%0.12%newJun 30, 2026
🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors3.89 M$10 M2.1%0.01%newJun 30, 2026
🇺🇸 Federated Hermes Kaufmann Small Cap FundFederated Advisory Services Company3.57 M$8 M1.9%0.28%no changeJul 31, 2026
🇺🇸 Federated Hermes Kaufmann Small Cap FundFederated Advisory Services Company2.38 M$5 M1.3%0.19%no changeJul 31, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.1.95 M$5 M1.0%<0.01%+47%Jun 30, 2026
🇺🇸 Eventide Healthcare & Life Sciences FundEventide Asset Management, LLC1.93 M$5 M1.0%0.29%−33%Jun 30, 2026
🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC1.68 M$4 M0.89%0.01%newJul 31, 2026
🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors1.21 M$3 M0.64%0.02%newJun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC613,458$2 M0.33%<0.01%+91%May 31, 2026
🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC646,552$1 M0.34%<0.01%newJul 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors514,160$1 M0.27%0.09%newJun 30, 2026
🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc.372,024$1 M0.20%0.01%newJul 31, 2026
🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC286,234$1 M0.15%0.01%newJun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC215,714$1 M0.11%<0.01%+91%May 31, 2026
🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC189,048$1 M0.10%0.02%newJun 30, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC179,955$0 M0.10%<0.01%+118%May 31, 2026
🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors169,022$0 M0.09%<0.01%newJun 30, 2026
🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC203,812$0 M0.11%0.01%newJul 31, 2026
🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC165,365$0 M0.09%0.01%newJun 30, 2026
🇺🇸 Direxion Daily S&P Biotech Bull 3X SharesRAFFERTY ASSET MANAGEMENT, LLC167,199$0 M0.09%0.08%newJul 31, 2026
🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc.157,253$0 M0.08%<0.01%+118%Jul 31, 2026
🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation111,400$0 M0.06%0.01%newJun 30, 2026
🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust99,542$0 M0.05%<0.01%newMay 31, 2026
🇺🇸 EA Bridgeway Omni Small-Cap Value ETFEmpowered Funds, LLC d/b/a EA Advisers91,234$0 M0.05%0.01%no changeJun 30, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.88,375$0 M0.05%<0.01%+172%Jun 30, 2026
🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc.78,781$0 M0.04%0.01%newJun 30, 2026
🇺🇸 Invesco RAFI US 1500 Small-Mid ETFInvesco Capital Management LLC94,188$0 M0.05%<0.01%+62%Jul 31, 2026
🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP83,973$0 M0.04%<0.01%+129%Jul 31, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.66,483$0 M0.04%<0.01%no changeJun 30, 2026
🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC72,842$0 M0.04%0.01%newJul 31, 2026
🇺🇸 U.S. Small Cap PortfolioDimensional Fund Advisors LP71,948$0 M0.04%<0.01%+121%Jul 31, 2026
🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC57,028$0 M0.03%0.01%newJun 30, 2026
🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP67,899$0 M0.04%<0.01%newJul 31, 2026
🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc.54,500$0 M0.03%<0.01%newJun 30, 2026
🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC51,359$0 M0.03%0.01%newJun 30, 2026
🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC43,584$0 M0.02%0.01%newJun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC38,689$0 M0.02%<0.01%+24%May 31, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC34,565$0 M0.02%0.04%newJun 30, 2026
🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS33,911$0 M0.02%0.01%newJun 30, 2026
🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC31,671$0 M0.02%0.01%newJun 30, 2026
🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC27,620$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC27,620$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc.24,048$0 M0.01%0.01%newJun 30, 2026
🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc.23,089$0 M0.01%0.01%newJun 30, 2026
🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC26,476$0 M0.01%<0.01%newJul 31, 2026
🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC20,846$0 M0.01%0.01%newJun 30, 2026
🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC20,614$0 M0.01%0.01%newJun 30, 2026
🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC18,764$0 M<0.01%0.01%newJun 30, 2026
🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC17,077$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc.19,348$0 M0.01%<0.01%+47%Jul 31, 2026
🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC17,931$0 M<0.01%0.01%newJul 31, 2026
🇺🇸 iShares Total U.S. Stock Market Index FundBlackRock Advisors, LLC17,417$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management13,896$0 M<0.01%0.01%newJun 30, 2026
🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC12,220$0 M<0.01%0.01%newJun 30, 2026
🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS13,473$0 M<0.01%0.01%newJul 31, 2026
🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC10,514$0 M<0.01%0.01%newJun 30, 2026
🇺🇸 PD Small-Cap Value Index PortfolioPacific Life Fund Advisors LLC10,073$0 M<0.01%0.02%newJun 30, 2026
🇺🇸 SmallCap Value Fund IIPrincipal Global Investors, LLC9,500$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC6,899$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Small-Cap Equity PortfolioPacific Life Fund Advisors LLC5,804$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC5,333$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Nationwide Fundamental All Cap Equity PortfolioNATIONWIDE FUND ADVISORS5,973$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 SA U.S. Small Company FundFocus Advisor Solutions, LLC3,918$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc.3,865$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC2,901$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC2,215$0 M<0.01%<0.01%+40%Jun 30, 2026
🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC1,878$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 State Street Balanced Index FundSSGA Funds Management, Inc.1,810$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC1,377$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC915$0 M<0.01%<0.01%+44%Jul 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 71 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Ovid Therapeutics Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$29 K
2 sales, 2 insiders
Net, 12 months
-$29 K
open market only
Insiders on file
15
since
$50 K-$29 K$0Mar 2024: bought $50 K (1 trades), sold $0 (0 trades)Mar 24Jan 2025: bought $5 K (1 trades), sold $0 (0 trades)Jan 25Feb 2025: bought $0 (0 trades), sold $5 K (2 trades)FebFeb 2026: bought $0 (0 trades), sold $29 K (2 trades)Feb
Bought (open market)Sold (open market)Hover a month for the totals
Ovid Therapeutics Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Charles Ross CarterChief Financial OfficerGrant or award+50,000——94,375Form 4
filed Bart FriedmanDirectorGrant or award+8,789$2.560$22 K8,789Form 4
filed Stelios PapadopoulosDirectorGrant or award+17,578$2.560$45 K217,578Form 4
filed Kevin Joseph FitzgeraldDirectorGrant or award+17,578$2.560$45 K17,578Form 4
filed Jeremy M. LevinExecutive Chairman, DirectorOption exercise+47,333$1.400$66 K3.74 MForm 4
filed Jeffrey A. RonaCBFOGrant or award+68,125——156,313Form 4
filed Jeffrey A. RonaCBFOSell-8,541$1.450$12 K88,188Form 4
filed Margaret A. AlexanderPresident and CEO, DirectorSell-11,656$1.450$17 K61,750Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Ovid Therapeutics Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
18.1 M
13.9% of shares · 8.2 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-2.15 reverse split in the period to

Fails to deliver

  • : 17,077 shares at $2.26
  • : 388 shares at $2.19
  • : 1,826 shares at $2.34
  • : 366 shares at $2.54
  • : 4,202 shares at $2.71

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Ovid Therapeutics Inc. scorecard#

Passes 6 of the 17 checks that could be worked out: strongest in growth (3 of 4), weakest in valuation (0 of 5). Fiscal year 2025; market cap of Oct 16, 2026.

  • Valuation0 of 5
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' median3.3×Price to book 3.3× against Biotechnology's median of 2.9×.
    • ✗Price to sales below its peers' median58.8×Price to sales 58.8× against Biotechnology's median of 8.7×.
    • ✗Free cash flow yield above 5%-9.0%Free cash flow is -9.0% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth3 of 4
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • ✓Revenue up more than 5% a year over three years69.1%69.1% a year over the three years to fiscal 2025.
    • ✓Faster growth over three years than its peers' median69.1%69.1% a year against Biotechnology's median of 12.9% (181 companies).
    • –Earnings per share grew in the newest yearEarnings per share of two years are not on file.
    • ✓Net income higher than five years earlier-$17 M-$17 M in fiscal 2025 against -$81 M in 2020.
    • ✗Revenue rose in at least four of the last five years3 of 5Revenue rose in 3 of the five years to fiscal 2025.
  • Profitability1 of 5
    • ✗Profitable in the newest year-$17 MNet income -$17 M in fiscal 2025.
    • ✗Profitable in each of the last five years1 of 5Profitable in 1 of the five years to fiscal 2025.
    • ✗Operating margin above its peers' median-585.4%-585.4% against Biotechnology's median of -60.5% (243 companies).
    • ✗Return on equity above 15%-17.5%-17.5% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✓Operating margin wider than three years earlier-585.4%-585.4% in fiscal 2025 against -3703.3% in 2022.
  • Financial health2 of 3
    • ✓Short-term assets cover short-term liabilities9.0×Current ratio 8.97 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✓Altman Z-score outside the distress zone9.29Z-score 9.29 (safe zone) for fiscal 2025.
  • Shareholder returnsnot known
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • –Share count up no more than 2% in a yearShare counts of two years are not on file.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Ovid Therapeutics Inc.'s statements, beside the median of Biotechnology.

Ovid Therapeutics Inc.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-585.4%-60.5%
Net margin-240.1%-68.9%
Return on equity-17.5%-61.0%
Revenue growth, 3 years a year69.1%12.9%
Free cash flow margin-528.7%-61.5%

3of 7on the Piotroski tests of financial strength

  • Net loss of $17 million, the 4th loss-making year in a row.
  • Free cash flow was negative: -$38 million.

Ovid Therapeutics Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Ovid Therapeutics Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue7.30.60.4r1.520813————
Research and development263729r2547634234509.6
General and administrative242631r32373119191513
Operating expenses506260r57849461536523
Operating income−42−62−59r−56124−81−61−53−65−23
Interest and finance income2.03.94.9———————
Other non-operating income (expense)25356.9r1.4−0.0—0.91.00.20.1
Income before tax−17−26−52r−54124−81————
Income tax00001.30000—
Net income attributable to shareholders−17−26−52r−54123−81−60−52−65−22
Earnings per share, basic——-0.74-0.771.78-1.39—-2.11-3.35-2.28
Earnings per share, diluted——-0.74-0.771.76-1.39—-2.11-3.35-2.28
Shares, weighted average (basic)——71706758————
Shares, weighted average (diluted)——71706858—25199.8
Balance sheet
Cash and cash equivalents132627r451887242368752
Short-term investments562779r840—355.0——
Other current assets4.72.93.8r2.42.72.71.92.2r1.50.2
Current assets7456110r1311907580448952
Property, plant and equipment0.30.40.8r1.10.20.10.10.10.10.0
Right-of-use (leased) assets121314r150—————
Other intangible assets0r0.1r0.2r0.20.2r0.3r0.50.4r0.10.1r
Investments in associates———5.11.60————
Long-term investments—2118r5.61.60————
Total assets15192144r1551957681488953
Accounts payable2.03.2r3.7r2.07.15.43.33.82.00.9
Current liabilities8.31111r7.01522118.86.03.7
Lease liabilities (non-current)121315r160—————
Total liabilities202456r231532118.8——
Retained earnings−322−304−278r−226−171−294−213−153−101−36
Shareholders' equity1316888r132r1804470398349
Total liabilities and equity15192144r1551957681488953
Shares outstanding13071717070665525259.8
Cash-flow statement
Depreciation and amortization0.30.60.6r0.50.20.30.30.10.10.1
Share-based compensation4.86.37.3r6.65.17.55.27.16.43.6
Cash from operating activities−38−56−46r−55119−52−51−46−31−18
Capital expenditure0−0.1−0.0r−1.2−0.2−0.1−0.1−0.0−0.0−0.0
Cash from investing activities−5055−2.6r−88−1.835−30−5.4−0.0−0.2
Shares issued————04764———
Cash from financing activities750.631r0.20.947870.367−0.0
Change in cash−13−0.7—−143118305.4−5135−18
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Ovid Therapeutics Inc. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Business segments

  • Reportable$7 M100%

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Executive pay at Ovid Therapeutics Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$1.9 M
Dr. Levin
Other top executives, average
$996 K
the CEO earned 1.9× this
$100 invested is now
$88
Ovid Therapeutics Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Dr. Levin$1.9 M$3.7 M$996 K$88
2024Margaret A. Alexander$2.8 M$36 K$1.6 M$29
2023Margaret A. Alexander$2.1 M$3.0 M$1.1 M$100

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Ovid Therapeutics Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling

Delisting notice 1 · Directors and officers 6 · Material agreement 2 · Unregistered share sale 2 · Bylaws or fiscal year changed 1 · Shareholder vote 3 · Results announced 5

Ovid Therapeutics Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Directors and officers8-K
Shareholder vote8-K
Directors and officers8-K
Material agreementUnregistered share saleResults announced8-K
Shareholder vote8-K
Directors and officersResults announced8-K
Material agreementUnregistered share saleBylaws or fiscal year changed8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Directors and officers8-K
Delisting notice8-K
Directors and officers8-K
Directors and officers8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026

Acquisitions and funding#

3 private funding rounds before listing

Private share sales · funding history

Private share sales of Ovid Therapeutics Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jan 2017$26 MNo. 3$10 to $50 million1equitySEC
Aug 2015$75 MNo. 2$50 to $250 million50equitySEC
Oct 2014$5 MNo. 1$2 to $10 million5equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Lobbying by Ovid Therapeutics Inc.#

$20 K spent on lobbying the US Congress and federal agencies in 2023.

Lobbying, 2023
$20 K
#1,336 among companies on value.today
Own lobbyists
No
only outside firms
Firms hired
1
in 2023
2026 so far
—

Lobbying firms hired in 2023

THE KPM GROUP DC LLC $20 K

Ovid Therapeutics Inc.: lobbying spending by year
YearSpendingOwn lobbyistsReports
2023$20 K—1
2022$80 K—4
2021$84 K—4
2020$30 K—4
2019$0—1

Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Ovid Therapeutics”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero

H-1B hiring at Ovid Therapeutics Inc.#

1 labor condition applications certified in fiscal 2024 for 1 positions, at a median wage of $160 K a year.

Certified, FY2024
1
#1,923 among companies on value.today
Worker positions
1
Median wage offered
$160 K
a year, full-time
Applications filed
1
Ovid Therapeutics Inc.: most frequent H-1B job titles in fiscal 2024
Job titlePositionsMedian wage offered
Associate Director, Program ManagementMedical Scientists, Except Epidemiologists1$160 K

Where: Boston, MA 1

Ovid Therapeutics Inc.: labor condition applications by fiscal year
Fiscal yearCertifiedPositionsMedian wageFiled
FY202411$160 K1
FY202122$290 K2

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as OVID THERAPEUTICS INC.

Layoffs at Ovid Therapeutics Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
17
2024–2024
Latest
17 people
2024-06-27
Ovid Therapeutics Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2024·····17······17
Ovid Therapeutics Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
17 people (43% of workforce)Restructuring planSEC 8-K“The Company will reduce its workforce by 17 people, or approximately 43% of the Company’s existing headcount, to preserve cash resources.”Filing

Source: State WARN notices and SEC 8-K item 2.05

Discuss Ovid Therapeutics Inc.#

2 automatic updates and 0 member comments. Sign in to comment and react.

  • Results announced on 10 November 2026automatic update · Nov 10, 2026

    Ovid Therapeutics Inc. announced results on 10 November 2026 (SEC Form 8-K, item 2.02). For the quarter ended 30 September 2026: a net loss of $21 million.

  • Mutual funds: 70 funds hold $84 millionautomatic update · Jul 31, 2026

    70 mutual funds in 1 country hold shares of Ovid Therapeutics Inc. worth $84 million, about 17.3% of the company (funds' newest reports, up to 31 July 2026). Since their previous reports 66 funds added shares and 2 sold; on balance they bought $46 million. Share splits are not counted as trading.

How Ovid Therapeutics Inc. compares in Biotechnology

  • Market cap$427 M · higher than 55% of 726
  • Revenue$7 M · higher than 39% of 647
  • Net margin-240.1% · higher than 24% of 408
  • Revenue growth1171.9% · higher than 98% of 438
  • Price / sales58.8× · lower than 16% of 339
  • Price / book3.3× · lower than 45% of 534
  • FCF yield-9.0% · higher than 60% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Ovid Therapeutics Inc.🇺🇸$427 M—-240.1%+1171.9%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 16, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of December 31, 2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Ovid Therapeutics Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Ovid Therapeutics Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Ovid Therapeutics Inc.? Suggest a correction